MedTrace Logo

Quantum Menstrual Health Monitoring Study

NCT05936840 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2024-10-28

No results posted yet for this study

Summary

The Quantum Menstrual Health Monitoring Study will measure four key reproductive hormones in the urine to characterize patterns that predict and confirm ovulation, referenced to serum hormones and the gold-standard of the ultrasound day of ovulation in participants with regular cycles. These normal cycles will provide a reference for comparison to irregular cycles in polycystic ovarian syndrome (PCOS) and athletes. Clinical signs in the menstrual cycle (e.g. menstrual bleeding, temperature) as well as vital sign and sleep patterns will also be referenced to hormonal changes.

Conditions

  • Menstrual Cycle Abnormal
  • Polycystic Ovary Syndrome
  • Athletes

Interventions

DEVICE

Mira Monitor tracking

Using the Mira monitor to track the menstrual cycle

Sponsors & Collaborators

  • Patricia Doyle-Baker

    collaborator UNKNOWN

  • Quanovate Tech Inc.

    lead INDUSTRY

Principal Investigators

  • Thomas Bouchard, MD · University of Calgary

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-05-01
Primary Completion
2025-05-01
Completion
2026-05-01
FDA Device
Yes

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05936840 on ClinicalTrials.gov